The current treatments for the PCa include radical surgery8, external beam radiotherapy7, brachytherapy9, local treatment of experimental PCa10, endocrine therapy11, and chemotherapy12, etc. Serum prostate-specific antigen (PSA) is now commonly used as the preferred marker for screening PCa, with low specificity13. This evidence concerns the gene KLK3 and posterior cortical atrophy.